Comparing Intravenous Famotidine and Oral Antacids to Treat Dyspepsia in the Emergency Department

What this Trial Is About

Researchers are evaluating two treatments for dyspepsia, a condition causing upper abdominal pain, in patients visiting the Emergency Department. The study compares intravenous famotidine, an H2 receptor antagonist, with oral antacids (Maalox/Mylanta) to see how they reduce pain levels. The goal is to understand which treatment lowers pain more effectively within one hour based on a verbal numerical pain scale. Participants will be randomly assigned to receive either 20 mg of intravenous famotidine or 30 ml of oral Maalox/Mylanta. Pain will be measured at five time points: 0, 15, 30, 45, and 60 minutes after receiving the medication. The study is single-blind, meaning the investigator measuring pain will not know which treatment the patient received. After the 60-minute study period, additional pain medication may be given if needed. During the study, researchers will collect information on pain severity, patient satisfaction with their assigned medication, and whether rescue medications were needed. The main outcome is the verbal numerical pain score at one hour. The study plans to enroll about 80 participants aged 18 and older who have dyspepsia and significant upper abdominal pain. The total participation lasts for one hour after treatment administration.

Famotidine and Antacids for Treatment of Dyspepsia